Probabilistic cost-effectiveness results
| Treatment | Cryoablation | AADs | Incremental |
| Cost (per patient) | £21 301 (£19 432 to £23 264) | £20 661 (£18 395 to £23 174) | £641 (-£1210 to £2364) |
| QALYs (per patient) | 11.47 (10.88 to 11.99) | 11.30 (10.65 to 11.88) | 0.17 (0.04 to 0.35) |
| ICER | £3783 (£710 to £36 753) | ||
| NMB | £2746 (-£665 to £7023) | ||
| Probability of cost-effectiveness at a threshold of £20 000 per QALY gained | 89.5% | ||
| Probability of cost-effectiveness at a threshold of £30 000 per QALY gained | 94.3% | ||
AADs, antiarrhythmic drugs; CrI, credible interval; ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit; QALY quality adjusted life-year.